MedTrace Logo

Personalized Risk Evaluation and Diagnosis (Using Corus CAD or ASGES) in the Coronary Tree

NCT00500617 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4350

Last updated 2019-01-31

No results posted yet for this study

Summary

The PREDICT study is to develop and validate a diagnostic blood ASGES (age, sex, gene expression score) or Corus CAD for atherosclerotic coronary artery disease (CAD). The Corus CAD (Age/Sex/Gene Expression score - ASGES) will use quantitative real-time PCR (RT-PCR) to quantify the expression of multiple genes from circulating peripheral blood cells to assess the presence of clinically significant CAD in a patient.

Conditions

Interventions

DIAGNOSTIC_TEST

Corus CAD (ASGES)

Age/Sex/Gene Expression Score - ASGES

Sponsors & Collaborators

  • CardioDx

    lead INDUSTRY

Principal Investigators

  • Mark Monane, MD FACP CMQ · CardioDx

Eligibility

Min Age
21 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2010-01-31
Completion
2011-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00500617 on ClinicalTrials.gov